Libmeldy market study points to faster growth in rare disease gene therapy

The Business Research Company says the global Libmeldy market is poised to expand through 2035 as gene therapy, newborn screening and rare disease diagnosis improve. North America led in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Libmeldy is a one-time gene therapy for metachromatic leukodystrophy, a rare and life-threatening genetic disorder. - Growth in this market reflects broader demand for curative treatments in rare diseases. - The report points to a larger shift toward earlier diagnosis, gene editing and ex vivo cell modification.

What happened: - The Business Research Company published its "Libmeldy Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - The report says the Libmeldy market is gaining attention as gene therapy breakthroughs and rare disease diagnostics advance. - A free sample of the report is available here. - The full report is available here.

The details: - Libmeldy, also called atidarsagene autotemcel, is an ex vivo gene therapy. - The treatment uses a patient’s hematopoietic stem cells, modifies them to carry a working ARSA gene, and reinfuses them. - The goal is to restore arylsulfatase activity and stop the buildup of sulfatides that damage the nervous system and other organs. - Historical market growth has been driven by better identification of rare genetic diseases, progress in hematopoietic stem cell manipulation, early positive gene therapy trial results, orphan-drug incentives and better diagnostic screening programs. - Future growth is expected to be supported by more gene therapy approvals, higher investment in rare disease research, broader newborn screening, stronger demand for curative therapies and continued innovation in gene editing. - Key trends include one-time treatments, early genetic diagnosis, more ex vivo cell modification, personalized medicine and stronger regulatory support for advanced therapies. - The report says increasing metachromatic leukodystrophy cases is a major growth driver. - A February 2024 report in the Journal of Managed Care & Specialty Pharmacy estimated about 2,500 people in the U.S. have MLD. - That same source put global incidence at between 1 in 40,000 and 1 in 160,000 live births.

Between the lines: - The market outlook is tied less to broad drug demand and more to a small patient pool with severe unmet need. - The commercial case for Libmeldy depends on diagnosis improving early enough for treatment to have the most impact. - The report also suggests the competitive landscape will favor companies with advanced manufacturing, genetic testing and cell-engineering capabilities.

What's next: - North America is expected to remain a major market, but Asia-Pacific is forecast to grow the fastest. - The report covers Asia-Pacific, Western and Eastern Europe, North and South America, and the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The Business Research Company also invites inquiries from its published contact channels.

The bottom line: - Libmeldy sits at the center of a fast-evolving rare disease therapy market where diagnosis, access and gene therapy innovation will determine future growth.